Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | CHRND | Q07001 | 5/20 | 0.43 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.43 |
| ▸ | CHRNG | P07510 | 1/20 | 0.43 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16656679 | 1.00 | GRIA1 (0.46) | GRIA1CTSLOPRD1OPRM1OPRK1 | |
| SCHEMBL16217709 | 1.00 | GRIA1 (0.46) | GRIA1CTSLOPRD1OPRM1OPRK1 | |
| SCHEMBL15133715 | 0.90 | MME (0.47) | GRIA1CTSLOPRD1OPRM1OPRK1 | |
| SCHEMBL16656682 | 0.86 | CTSS (0.54) | CTSLCTSSCTSK | |
| SCHEMBL22695725 | 0.86 | CTSS (0.54) | CTSLCTSSCTSK | |
| SCHEMBL23135666 | 0.85 | CTSL (0.44) | GRIA1CTSLOPRD1OPRM1OPRK1 | |
| SCHEMBL16217879 | 0.85 | GRIA1 (0.44) | GRIA1CTSLOPRD1OPRM1OPRK1 | |
| SCHEMBL16846635 | 0.85 | GRIA1 (0.46) | GRIA1CTSLCTSSCTSKCHRND | |
| SCHEMBL9968605 | 0.85 | OPRD1 (0.55) | GRIA1CTSLOPRD1OPRM1OPRK1 | |
| SCHEMBL8022821 | 0.82 | MMP1 (0.51) | CTSLESR1ESR2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220737-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023168296-A2 | CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-4219718-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3862362-A2 | CONJUGATES OF MODIFIED ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR MODULATING PKK EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3137091-B1 | CONJUGATES OF MODIFIED ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3730619-A1 | COMPOSITIONS AND METHODS FOR MODULATION OF TARGET NUCLEIC ACIDS | Ionis Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3137115-B1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | IONIS PHARMACEUTICALS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3690049-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3608406-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3564374-A1 | COMPOSITIONS AND METHODS FOR MODULATION OF TARGET NUCLEIC ACIDS | Ionis Pharmaceuticals, Inc. (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3546579-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | Ionis Pharmaceuticals, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |